7,500 Shares in Biogen Inc. $BIIB Purchased by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 7,500 shares of the biotechnology company’s stock, valued at approximately $1,375,000.

Several other institutional investors also recently bought and sold shares of BIIB. Rothschild Investment LLC raised its stake in shares of Biogen by 12.3% during the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after buying an additional 56 shares during the period. Itau Unibanco Holding S.A. increased its holdings in Biogen by 24.4% in the 4th quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 66 shares in the last quarter. Advisory Services Network LLC raised its position in Biogen by 3.9% during the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 68 shares during the period. Davis Investment Partners LLC lifted its holdings in Biogen by 1.7% during the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after purchasing an additional 71 shares in the last quarter. Finally, Optas LLC lifted its holdings in Biogen by 4.5% during the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 73 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Stock Up 3.0%

BIIB stock opened at $216.12 on Friday. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. The firm has a 50-day moving average of $196.09 and a two-hundred day moving average of $186.83. Biogen Inc. has a 12 month low of $121.05 and a 12 month high of $219.72. The company has a market cap of $31.91 billion, a price-to-earnings ratio of 23.19 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the business earned $3.02 earnings per share. The business’s revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, analysts forecast that Biogen Inc. will post 13.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BIIB has been the subject of a number of research reports. JPMorgan Chase & Co. boosted their target price on shares of Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. Oppenheimer raised their price target on shares of Biogen from $275.00 to $300.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. Needham & Company LLC lifted their price objective on Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a report on Monday. Mizuho cut their price objective on Biogen from $236.00 to $221.00 and set an “outperform” rating for the company in a research note on Monday, June 15th. Finally, The Goldman Sachs Group increased their target price on Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a report on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $217.41.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.